Journal Watch · Frontiers in Immunology · 2026

Development of a GMMA-based candidate vaccine against invasive nontyphoidal <i>Salmonella</i> disease.

Additionally, the highest envisioned human dose of iNTS-GMMA was well tolerated in a GLP repeated-dose toxicology study in rabbits.<h4>Conclusions</h4>These data supported clinical evaluation of this urgently needed vaccine against iNTS disease in sSA.

Citiulo F, Koeberling O, Rossi O et al.Frontiers in Immunology3 min readPharma relevance 50/100

DOI: 10.3389/fimmu.2026.1821495PMID: 42311694Study type: preclinical (animal / model) study

TL;DR

Additionally, the highest envisioned human dose of iNTS-GMMA was well tolerated in a GLP repeated-dose toxicology study in rabbits.<h4>Conclusions</h4>These data supported clinical evaluation of this urgently needed vaccine against iNTS disease in sSA.

Key findings

  • Typhimurium and <i>S</i>.
  • Enteritidis LPS O-antigens, the target antigens of the vaccine.
  • Moreover, animal sera elicited strong <i>in vitro</i> bactericidal activity against <i>S</i>.
  • Typhimurium and <i>S</i>.
  • Enteritidis strains.

Numbers at a glance (from the abstract)

14.7%80%

Every figure above is taken verbatim from the abstract below. Check the full text for denominators, confidence intervals and subgroup detail.

What they did

A simple two-step filtration process was used to purify the GMMA drug substances. Subsequently, the <i>S</i>. Typhimurium GMMA and <i>S</i>. Enteritidis GMMA were individually formulated on Alhydrogel to produce the drug products. Mixing of the two components prior to injection results in the iNTS-GMMA vaccine candidate.<h4>Results</h4>The iNTS-GMMA vaccine candidate induced in mice and rabbits high levels of IgG anti-<i>S</i>.

Full abstract (original)

Background: <h4>Introduction</h4>Invasive nontyphoidal <i>Salmonella</i> (iNTS) disease is one of the most common causes of bacteremia in sub-Saharan Africa (sSA), mostly affecting children less than 5 years of age and with an associated 14.7% case fatality ratio. This disease is responsible for 62,018 deaths worldwide annually with more than 80% of those occurring in sSA.<h4>Methods</h4>This work describes the pre-clinical development of a Generalized Modules for Membrane Antigens (GMMA)-based bivalent vaccine candidate against iNTS disease, known as iNTS-GMMA. <i>Salmonella enterica</i> serovars Typhimurium (<i>S</i>. Typhimurium) and Enteritidis (<i>S</i>. Enteritidis) were genetically modified to induce hyperblebbing of outer membrane vesicles, referred to as GMMA, with a penta-acylated lipid A of the lipopolysaccharide (LPS), characterized by a reduced induction of proinflammatory cytokine release from monocytes compared to GMMA carrying wild-type species of lipid A. GMMA derived from the genetically modified <i>Salmonella</i> strains were produced at scale with high yields and purity under both non-good manufacturing practice (GMP) conditions and under GMP conditions.

What they did: A simple two-step filtration process was used to purify the GMMA drug substances. Subsequently, the <i>S</i>. Typhimurium GMMA and <i>S</i>. Enteritidis GMMA were individually formulated on Alhydrogel to produce the drug products. Mixing of the two components prior to injection results in the iNTS-GMMA vaccine candidate.<h4>Results</h4>The iNTS-GMMA vaccine candidate induced in mice and rabbits high levels of IgG anti-<i>S</i>.

Results & conclusions: Typhimurium and <i>S</i>. Enteritidis LPS O-antigens, the target antigens of the vaccine. Moreover, animal sera elicited strong <i>in vitro</i> bactericidal activity against <i>S</i>. Typhimurium and <i>S</i>. Enteritidis strains. Additionally, the highest envisioned human dose of iNTS-GMMA was well tolerated in a GLP repeated-dose toxicology study in rabbits.<h4>Conclusions</h4>These data supported clinical evaluation of this urgently needed vaccine against iNTS disease in sSA.

Abstract © the authors / Frontiers in Immunology (2026). Reproduced here for discussion and indexing, with attribution. Read the original at https://doi.org/10.3389/fimmu.2026.1821495 · PubMed 42311694.

Why it matters for pharma & biotech

  • Directly relevant to teams in vaccines — the abstract reports new data in that space, so competitive and pipeline teams should read the full text.
  • As earlier-stage work, its near-term value is target validation and assay design rather than clinical decisions.
  • For searchers: the full abstract is reproduced below, so you can judge relevance before opening the publisher page.

Modalities & themes detected: vaccines

Limitations & what to check in the full text

  • This brief is based on the published abstract only. Effect sizes, subgroup results and safety detail in the full text may qualify the headline findings.
  • The work is preclinical. Results in animal or cell models frequently do not translate directly to human efficacy or safety.

Frequently asked questions

What did this Frontiers in Immunology study find?

Additionally, the highest envisioned human dose of iNTS-GMMA was well tolerated in a GLP repeated-dose toxicology study in rabbits.<h4>Conclusions</h4>These data supported clinical evaluation of this urgently needed vaccine against iNTS disease in sSA.

What type of study is this?

It is a preclinical (animal / model) study, published in Frontiers in Immunology in 2026. A simple two-step filtration process was used to purify the GMMA drug substances.

Where can I read the original paper?

The original is at the publisher via DOI 10.3389/fimmu.2026.1821495. PubMed ID: 42311694. BioStudioAI reproduces the abstract for discussion and links to the source.

How to cite the original: Citiulo F, Koeberling O, Rossi O et al.. Development of a GMMA-based candidate vaccine against invasive nontyphoidal &lt;i&gt;Salmonella&lt;/i&gt; disease.. Frontiers in Immunology (2026). DOI: 10.3389/fimmu.2026.1821495.
This brief: BioStudioAI Journal Watch, 29 October 2026. https://biostudioai.com/blog/papers/development-of-a-gmma-based-candidate-vaccine-against-invasive-nontyphoi-821495/

Reading papers is step one. Analysing the data is the work.

BioStudioAI turns raw lab files into QC'd results, statistics, figures, reports and slides — hosted on your servers, every number computed, nothing typed.

Open BioStudioAI More guides